The combinatory treatment with panobinostat and proteasome inhibitors also curtails protein levels in MM cells of HDAC1, another target molecule of Sp1, which may lead to further potentiation and prolongation of HDAC inhibition in cooperation with direct immediate enzymatic HDAC inhibition by panobinostat. Here, SP1 is linked to Miyoshi myopathy.